About
Maykin Ho, Ph.D., has served on Agios's board since June 2015 and has more than 30 years of experience in the healthcare and finance industries.
She was a venture partner at Qiming Venture Partners for ten years until July 2025, and previously held roles at Goldman Sachs from 1992 to 2015, including advisory director of global healthcare investment banking and partner and co-head of healthcare investment research. Earlier she held managerial positions at DuPont-Merck Pharmaceuticals. She received a Ph.D. in microbiology and immunology from the State University of New York, Downstate Medical Center.
Roles
Agios Pharmaceuticals, Inc.
Director · Current role
Jun 2015–present
Qiming Venture Partners
Venture partner · Venture capital firm in China and Hong Kong; served for ten years until July 2025.
—
Goldman Sachs
Advisory director, global healthcare investment banking; partner and co-head of healthcare investment research · Also served as senior biotechnology research analyst.
1992 – 2015
DuPont-Merck Pharmaceuticals / DuPont de Nemours
Managerial positions
—
Goldman Sachs Group
Partner; Senior Biotechnology Analyst; Co-Head of Healthcare, Global Investment Research; Advisory Director, Healthcare Investment Banking · Now retired.
—
External Roles
BioMarin Pharmaceutical
Director
—
Kyntra Bio (formerly FibroGen)
Director
—
Neumora Therapeutics
Director
—
Parexel International
Director
—
Pelage Pharmaceuticals
Director
—
Aaron Diamond AIDS Research Center
Board of Directors and Chair of the Audit Committee
—
FibroGen, Inc.
Board of Directors
—
BioMarin Pharmaceutical
Board of Directors
—
Director Compensation
FY 2025
Fees earned or paid in cash
$65,000
Also at Agios Pharmaceuticals, Inc.